SHARESIFT
Healthcare · data ~15-min delayed
190.01 USD +0.57%
| Price | 190.01 USD |
| Day change | +0.57% |
| Market cap | 75.86B |
| 52-week range | 22.28 – 208.9 |
| P/E (trailing) | — |
| Dividend yield | 0.00% |
| Payout ratio | 0.00% |
| Return on equity | -39.00% |
| Debt / equity | 19% |
| Beta | 1.11 |
| Sector | Healthcare |
| Value score | 21 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Moderna, Inc. (MRNA) scores 21/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It is classified in Healthcare. It does not currently pay a dividend. Return on equity is -39%, with debt at 19% of equity. On its filings it passes 2 of the nine Piotroski checks, which points to deteriorating fundamentals. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 2 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 15.03 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.